Cx Institutional Nektar Therapeutics Transaction History

Cx Institutional

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 12, 2021	SELL	$15.77 - $19.03 $1,103 - $1,332	-70 Closed	0 $0
Q3 2020 Oct 13, 2020	SELL	$16.59 - $24.79 $16 - $24	-1 Reduced 1.41%	70 $1,000
Q2 2020 Aug 06, 2020	BUY	$16.86 - $23.44 $1,197 - $1,664	71 New	71 $2,000
Q1 2020 Apr 29, 2020	SELL	$14.47 - $27.96 $1,258 - $2,432	-87 Closed	0 $0
Q3 2019 Oct 10, 2019	BUY	$16.91 - $36.27 $1,014 - $2,176	60 Added 222.22%	87 $2,000
Q2 2019 Jul 17, 2019	BUY	$31.0 - $36.3 $124 - $145	4 Added 17.39%	27 $1,000
Q1 2019 Apr 03, 2019	BUY	$31.58 - $46.35 $726 - $1,066	23 New	23 $1,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Cx Institutional, based on Form 13F filings with the SEC.

Stay updated on Cx Institutional with notifications on news.